Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Industrials, Technology and Basic Materials sectors led shares lower. At the close in NYSE, the...
Gainers: WMLP +172%. AVGR +53%. CARA +32%. BDR +28%. TIF +20%. RL +17%. MDXG +16%. AMDA +14%. USAT +13%. DCAR +13%. Losers: FWP -30%. RRGB -19%. CDTI -19%. CMTA -16%. ARDX...
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Oil & Gas, Industrials and Basic Materials sectors led shares lower. At the close in NYSE, the...
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) amended its collaboration agreement with UK-based pharma giant AstraZeneca (NYSE:AZN) related to development and commercialization...
Ardelyx, Inc. (NASDAQ:ARDX) announced that it has received FDA approval for Ibsrela (tenapanor) as a treatment for irritable bowel syndrome with constipation (IBS-C) in adults....
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Buy||Strong Buy||Buy||Buy||Buy|
|Technical Indicators||BUY||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
|Summary||Buy||Strong Buy||Strong Buy||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Advance Block Bearish||1M||1||Oct 19|
|Three Outside Up||1M||2||Sep 19|
|Three Outside Up||1D||2||Nov 08, 2019|
|Bullish Engulfing||1M||3||Aug 19|
|Doji Star Bearish||1D||5||Nov 05, 2019|
|Applied DNA Sciences Inc||11.850||14.140||5.775||+7.400||+166.29%||6.42M||11:32:04|
Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.Read More
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.